Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02716805
Title Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Facility New York New York 10029 United States Details
Research Facility New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from for the field